OnKure Therapeutics (OKUR) Competitors $2.85 +0.02 (+0.71%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OKUR vs. SPRO, CGEN, ACOG, KYTX, LXEO, IKT, ALEC, EPRX, BDTX, and KRROShould you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include Spero Therapeutics (SPRO), Compugen (CGEN), Alpha Cognition (ACOG), Kyverna Therapeutics (KYTX), Lexeo Therapeutics (LXEO), Inhibikase Therapeutics (IKT), Alector (ALEC), Eupraxia Pharmaceuticals (EPRX), Black Diamond Therapeutics (BDTX), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. OnKure Therapeutics vs. Its Competitors Spero Therapeutics Compugen Alpha Cognition Kyverna Therapeutics Lexeo Therapeutics Inhibikase Therapeutics Alector Eupraxia Pharmaceuticals Black Diamond Therapeutics Korro Bio Spero Therapeutics (NASDAQ:SPRO) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends. Does the media refer more to SPRO or OKUR? In the previous week, Spero Therapeutics had 3 more articles in the media than OnKure Therapeutics. MarketBeat recorded 5 mentions for Spero Therapeutics and 2 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.89 beat Spero Therapeutics' score of 1.12 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is SPRO or OKUR more profitable? Spero Therapeutics has a net margin of 3.30% compared to OnKure Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 4.03% beat OnKure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spero Therapeutics3.30% 4.03% 2.21% OnKure Therapeutics N/A -51.17%-47.11% Does the MarketBeat Community believe in SPRO or OKUR? Spero Therapeutics received 201 more outperform votes than OnKure Therapeutics when rated by MarketBeat users. However, 100.00% of users gave OnKure Therapeutics an outperform vote while only 69.67% of users gave Spero Therapeutics an outperform vote. CompanyUnderperformOutperformSpero TherapeuticsOutperform Votes20969.67% Underperform Votes9130.33% OnKure TherapeuticsOutperform Votes8100.00% Underperform VotesNo Votes Which has more risk and volatility, SPRO or OKUR? Spero Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Do insiders and institutionals believe in SPRO or OKUR? 25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 5.5% of Spero Therapeutics shares are owned by insiders. Comparatively, 2.3% of OnKure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings & valuation, SPRO or OKUR? Spero Therapeutics has higher revenue and earnings than OnKure Therapeutics. Spero Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpero Therapeutics$28.30M5.71$22.81M-$1.28-2.26OnKure TherapeuticsN/AN/A-$77.39M-$5.26-0.54 Do analysts prefer SPRO or OKUR? Spero Therapeutics presently has a consensus target price of $5.00, suggesting a potential upside of 73.01%. OnKure Therapeutics has a consensus target price of $32.33, suggesting a potential upside of 1,034.50%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe OnKure Therapeutics is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 SummarySpero Therapeutics beats OnKure Therapeutics on 11 of the 18 factors compared between the two stocks. Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKUR vs. The Competition Export to ExcelMetricOnKure TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.50M$6.94B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.238.7927.2619.97Price / SalesN/A263.06412.06157.64Price / CashN/A65.8538.2534.64Price / Book0.116.597.064.69Net Income-$77.39M$144.20M$3.24B$248.14M7 Day Performance-0.35%3.81%2.56%2.39%1 Month Performance46.15%11.10%8.75%6.06%1 Year PerformanceN/A3.95%31.30%13.57% OnKure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKUROnKure Therapeutics3.6549 of 5 stars$2.85+0.7%$32.33+1,034.5%N/A$38.50MN/A-0.23N/ANews CoveragePositive NewsSPROSpero Therapeutics3.8756 of 5 stars$2.76+10.4%$5.00+81.2%+88.6%$154.31M$28.30M39.43150Positive NewsShort Interest ↑High Trading VolumeCGENCompugen2.3792 of 5 stars$1.70-2.3%$4.00+135.3%-14.3%$151.70M$27.59M85.0070Positive NewsGap DownACOGAlpha Cognition1.7238 of 5 stars$9.17-2.2%$20.00+118.1%N/A$150.19M$2.93M-3.58N/AGap UpKYTXKyverna Therapeutics2.2135 of 5 stars$3.45+1.8%$18.50+436.2%-74.7%$149.11M$7.03M-1.0296LXEOLexeo Therapeutics3.8047 of 5 stars$4.38+12.9%$18.50+322.4%-74.3%$145.40M$650K-1.3958Positive NewsIKTInhibikase Therapeutics1.4971 of 5 stars$1.95-0.5%$6.50+233.3%+22.9%$144.97M$260K-0.736Positive NewsALECAlector3.5252 of 5 stars$1.44-3.4%$4.00+177.8%-63.1%$143.99M$88.34M-0.85270Short Interest ↑Analyst RevisionEPRXEupraxia Pharmaceuticals2.2979 of 5 stars$3.97+0.8%$10.50+164.5%+38.9%$142.32MN/A-5.5129BDTXBlack Diamond Therapeutics3.4727 of 5 stars$2.48-3.9%$14.60+488.7%-61.1%$141.02M$70M-1.8690Positive NewsGap UpKRROKorro Bio3.5686 of 5 stars$14.85+1.8%$102.43+589.8%-64.8%$139.46M$4.82M-1.5770Analyst RevisionGap Up Related Companies and Tools Related Companies Spero Therapeutics Alternatives Compugen Alternatives Alpha Cognition Alternatives Kyverna Therapeutics Alternatives Lexeo Therapeutics Alternatives Inhibikase Therapeutics Alternatives Alector Alternatives Eupraxia Pharmaceuticals Alternatives Black Diamond Therapeutics Alternatives Korro Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKUR) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
